TickerFacts.

Actuate Therapeutics, Inc. (ACTU): R&D Expense

Annual figures by period end, from SEC filings.

$10.29M
Year ended 2025-12-31
$8.94M
Trailing 12 months to 2026-06-30
$21.71M2023-12-31: $21.71M2024-12-31: $18.68M2025-12-31: $10.29M$10.29M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$10.29M-44.9%2026-03-26, From 2025-01-01
2024-12-31$18.68M-14.0%2026-03-26, From 2024-01-01
2023-12-31$21.71Mn/a2025-03-13, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Actuate Therapeutics, Inc. (ACTU)2025-12-31$10.29M-44.9%
Exicure, Inc. (XCUR)2025-12-31$3.29Mn/a
Biovie Inc. (BIVI)2026-06-30$13.96M+50.7%
Chemomab Therapeutics Ltd. (CMMB)2025-12-31$5.83M-48.5%
CalciMedica, Inc. (CALC)2025-12-31$15.23M+5.2%
Edesa Biotech, Inc. (EDSA)2025-09-30$3.67M+27.3%
Cellectar Biosciences, Inc. (CLRB)2025-12-31$11.50M-56.0%
Cingulate Inc. (CING)2025-12-31$9.77M+3.5%
NRX Pharmaceuticals, Inc. (NRXP)2025-12-31$3.78M-39.1%

Compare ACTU, XCUR, BIVI, CMMB side by side · Screen every company in Pharmaceutical Preparations ↗